Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Growth Opportunities are Expected to Drive the Glioblastoma Multiforme Market’s CAGR Through 2034?

There has been significant and robust expansion in the glioblastoma multiforme market in the past few years. Its growth trajectory suggests an increase from $2.50 billion in 2024 to $2.71 billion in 2025, projecting a compound annual growth rate (CAGR) of 8.3%. The historical period’s growth can be attributed to a surge in glioblastoma multiforme cases, improved healthcare facilities, heightened awareness, access to sophisticated therapies, and the increase in the elderly population.

Robust expansion is foreseen in the glioblastoma multiforme market over the upcoming years, rocketing to a valuation of $3.69 billion in 2029 with a compound annual growth rate (CAGR) of 8.1%. This anticipated surge during the forecast period can be credited to the rising incidence of brain and nervous system cancer cases, heightened adoption of surgical procedures, increasing awareness, early identification of the ailment, and the growth in research and development projects. Noteworthy trends projected for the forecast period incorporate medical technological advancements, progressing imaging techniques, personalized medical treatments, utilization of AI in diagnosis, as well as tech-based and scientific enhancements.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Glioblastoma Multiforme Market?

The growth of the glioblastoma multiforme market is anticipated to be propelled by the escalating incidences of brain disorders. Such disorders, which can cause cognitive, emotional or physical impairments, stem from structural or functional abnormalities in the brain. Factors contributing to the uptick in brain disorder cases include an aging demographic, extended lifespan, lifestyle choices and enhanced capacity for diagnosis. Gaining insights into brain disorders facilitates progress in glioblastoma multiforme (GBM) research, paving the way for superior early detection methods, novel therapeutic strategies, and enhanced patient prognoses. By investigating neurological ailments, researchers can discover genetic and molecular associations that play a part in the inception of GBM. Dementia Australia, a non-profit organization based in Australia, reported in February 2025 that about 433,300 Australians are suffering from dementia, a figure projected to balloon to 812,500 by 2054. Furthermore, early-onset dementia is affecting roughly 29,000 individuals in 2025, a number forecasted to climb to 41,000 by 2054. Consequently, the escalating cases of brain disorders are projected to catalyze the expansion of the glioblastoma multiforme market.

Explore Comprehensive Insights Into The Global Glioblastoma Multiforme Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

What Are the Leading Industry Players Dominating the Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

What Are the Latest Trends Leading to Disruption in the Glioblastoma Multiforme Market?

Prominent businesses in the glioblastoma multiforme market are concentrating on creating cutting-edge treatments, such as CAR T-cell therapies, to fulfil the unmet healthcare requirements of aggressive cancer. CAR T-cell treatments are a type of immunotherapy which involve altering a patient’s T-cells to efficiently identify and eliminate cancer cells. Chimeric Therapeutics Limited, a biotech firm based in Australia, for instance, initiated a Phase IB clinical study of CHM 1101 (CLXT CAR T) therapy for recurring or progressive glioblastoma multiforme (GBM) in June 2023. The trial, carried out at multiple sites, is designed to assess the safety and effectiveness of the therapy, and to establish the recommended Phase 2 dose. The initial Phase 1a results indicated disease stabilization, and the trial will expand on this to bolster further development. The firm intends to employ the experimental data to structure a registration trial and get regulatory advice.

Secure Your Global Glioblastoma Multiforme Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

What Are the Strategic Segments Comprising the Glioblastoma Multiforme Market and Their Growth Contributions?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Which Regions Are Significant to the Growth of the Glioblastoma Multiforme Market?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Glioblastoma Multiforme Market and Its Key Components?

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.

Browse Through More Similar Reports By The Business Research Company:

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Bleeding Disorder Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: